US98978V1035 - Common Stock
173.05 -3.82 (-2.16%)
NYSE:ZTS (9/27/2023, 12:24:30 PM)
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 13,800 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. The company commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The firm operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The firm market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
10 Sylvan Way
Parsippany NEW JERSEY 07054
CEO: Kristin C. Peck
Los Angeles, California 9-16-2023, DMF Group, Frankfurt, and its partner Corporate Finance Associates Worldwide (CFAW), Los Angeles, exclusively advised the shareholders of adivo GmbH, Puchheim near Munich, on the sale of 100% of their shares to Zoetis Inc. (NYSE: ZTS), Parsippany, NJ, near New York.
HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its buy ratings list. Read more here.
Don't let their diminutive-looking yields fool you -- these stocks are four of the fastest dividend growers in the S&P 500.
Here you can normally see the latest stock twits on ZTS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.